U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07318129) titled 'Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis' on Nov. 23, 2025.
Brief Summary: This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegener...